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Abstract
Background: The Magpie Trial, a randomised trial comparing magnesium sulphate with placebo
for women with pre-eclampsia. This paper describes methods used for follow up in the UK, and
presents additional data collected.
Methods: In the UK 774 women and their 827 children were included; excluded were women
discharged without a surviving child and families who opted out. General practitioners were sent a
questionnaire when the child was around 18 months old. When the child was two years, or older,
questionnaires asking about the health of the women and children were posted to families. A
sample of families was offered a home visit, during which the child was assessed using the Bayley
Scales of Infant Development.
Results: Of the women, 12 were lost to follow up and three died. Of the children, 12 were lost
to follow up, 5 were excluded and 19 died. General practitioners returned 688/759 (91%)
questionnaires, as did 619/759 (82%) women. Responses were largely comparable. 32 women had
serious morbidity potentially related to pre-eclampsia. 30% of children were reported to have been
admitted to hospital. There were no clear differences between the randomised groups in the child's
behaviour, women's fertility or use of health service resources.
Conclusion: Data presented here provide further reassurance about the longer term safety of
magnesium sulphate when used for women with pre-eclampsia. Postal questionnaires in the UK to
assess the longer term health and wellbeing of women and children recruited to trials are feasible,
and can achieve a high response rate. Responses from families and general practitioners were
comparable
Trial registration: Trial registration number of the Magpie Trial [ISRCTN86938761]
Background
Pre-eclampsia; a multisystem disorder of pregnancy usually
associated with raised blood pressure and proteinuria, com-
plicates 2–8% of pregnancies[1]. Although outcome is gen-
erally good, pre-eclampsia is a major cause of morbidity and
mortality for the woman and her child [2]. For example, it
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sions[3], two thirds of referrals to day care assessment
units[4] , and a quarter of obstetric admissions to intensive
care units[5]. Eclampsia is defined as the occurrence of one
or more convulsions superimposed on pre-eclampsia. Fortu-
nately in the UK eclampsia is rare, affecting around 1 in 2000
deliveries, although it is associated with a high morbidity
and mortality [6]. Pre-eclampsia and eclampsia together
account for 15% of direct maternal deaths in the UK, with
two-thirds related solely to pre-eclampsia [7].
The Magpie Trial compared magnesium sulphate with
placebo for women with pre-eclampsia[8]. This ran-
domised trial demonstrated that magnesium sulphate
more than halves the risk of eclampsia (relative risk (RR)
0.42, 95% confidence interval (CI) 0.29–0.60), and prob-
ably reduces the risk of maternal death before discharge
from hospital (RR 0.55, 95% CI 0.26–1.14). No substan-
tive harmful effects were apparent for the mother or baby,
in the short term.[8] Follow up at 18 months, or later,
found little evidence that in utero exposure to magnesium
sulphate is associated with an increase in the risk of death
or neurosensory disability for the child [9] , or in maternal
death or serious morbidity potentially related to pre-
eclampsia for the mother [10].
For the follow up study; methods for tracing and assessing
families were developed that could be implemented
across 19 countries and a range of settings.[11,12] Never-
theless, in the UK methods of follow up differed from
other countries in several ways; deaths were ascertained
through the national registration system; tracing and
assessment of UK women and children was co-ordinated
centrally, rather than through local co-ordinators; screen-
ing was by postal questionnaires and this included both
general practitioner and the family; and some additional
questions were used in the UK, but not in other countries.
This paper describes the methods used in the UK and
presents data collected only in the UK, which have not
been published previously.
Methods
Between July 1998 and November 2001, 804 women were
recruited to the Magpie Trial at 67 UK hospitals. Follow up
was from October 2002 until May 2004. Thirty women
were excluded from tracing leaving 774 eligible for follow
up (Figure 1). Overall, 841 children were born to women
recruited, of whom 14 were excluded (Figure 2) leaving 827
eligible for follow up. Of these, 638 children were born to
women randomised before delivery. Women and children
who died after discharge from hospital were included in the
overall analysis of outcome [9,10] but as the focus of this
paper is the questionnaires, these deaths are excluded here.
Ethics approval was from the Northwest Multicentre
Research Ethics Committee, as an amendment to the orig-
inal trial protocol. Women had been informed they might
be contacted for follow up before agreeing to recruitment,
so additional consent was not required. All women and
carers could opt out of the study at any time, if they
wished.
How families were traced
Ascertainment of deaths after discharge from hospital was
through the Office of National Statistics. Families were
contacted if there was at least one surviving child. If the
mother had died, the child's carer was contacted.
The families' current address was obtained from a range of
sources, including trial data collected at discharge from
hospital, the Office for National Statistics, and the
National Health Service Tracing Scheme. We wrote to each
woman describing the follow up study, enclosing a simple
card asking her to let us know if she changed address, and
giving her the opportunity to 'opt out'. This letter was sent
with either a birthday card for the child's first birthday, or
a greetings card.
How the children and women were assessed
The tools for screening and assessment of the children and
women are described in our protocol. [11] In the UK we
first sent a questionnaire to the general practitioner when
the child was 18 months old. This was also to check that
it was appropriate to contact the family. If the woman and
child had different general practitioners, both were con-
tacted. The general practitioner questionnaire included
questions about the child's general health since birth,
recent consultations (excluding routine assessments and
immunisations), neurosensory function, any diagnosis,
prescribed medication, and admission to hospital. A sep-
arate section asked about the mothers' health, possible
long-term sequelae of pre-eclampsia, prescribed medica-
tion, and admission to hospital. Those who did not
respond were sent reminders, or contacted by telephone.
When children were 2 years old, or more, the child's ques-
tionnaire was posted to the family, along with a second
questionnaire asking the mother about her health.
Reminders were sent after one month. If there was no
response, a second reminder was sent by recorded deliv-
ery, or the family was contacted by telephone.
The child's questionnaire incorporated the Ages and
Stages Questionnaires (ASQ)[13] with some additional
questions about the child's behaviour and use of health
care resources:
Behaviour
1) Does your child play happily with toys for up to 10
minutes?
2) Is your child frightened in new situations?Page 2 of 11
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Profile of women recruited in the UKFigure 1
Profile of women recruited in the UK.
804 women randomised 
626 before delivery 
178 after delivery
30 women excluded  
  17 no surviving children  
  12 opted out 
    1 child fostered 
12 women lost to follow up 
   8 left NHS 
   4 not traceable
3 women died after discharge 
from hospital 
   2 randomised before delivery  
   1 randomised after delivery
     774 women included in follow up study 
          605 randomised before delivery  
          169 randomised after delivery
759 women included  
    592 randomised before delivery  
    167 randomised after delivery 
Women with questionnaire responses  
      619 women’s questionnaire* 
      688 GP questionnaire 
      551 both women’s and GP questionnaire 
* 13 families returned the ASQ but not the Women’s questionnaire
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Profile of children born to women recruited in the UKFigure 2
Profile of children born to women recruited in the UK.
   
841 children born to women randomised 
           646 of women randomised before delivery 
           195 of women randomised after delivery 
 14 children excluded 
   13 families opted out 
    1 child fostered 
12 children lost to follow up  
   8 left NHS 
   4 not traceable
827 children included in follow up study 
   638 to women randomised before delivery 
   189 to women randomised after delivery
5 children excluded, as 
problem arising during 
conception or embryogenesis
19 children died  
   17 before discharge from hospital*
    2 after discharge from hospital**
791 children analysed
      594 women randomised before delivery 
      197 women randomised after delivery 
Children with questionnaire responses 
       659 child’s questionnaire***
       688 GP questionnaire 
       580 both child’s and GP questionnaire 
* 13 randomised before delivery 
** Randomised before delivery  
***Excludes 12 questionnaires that could not be scored 
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you are around?
4) Does your child cling to you when you are with
other people?
5) Does your child settle easily to sleep throughout the
night?
Options for response to questions 'Yes' 'Sometimes' 'No'
Use of health care resources
6) Has your child been prescribed any medicines to be
taken for more than two weeks?
If yes, please give their names ........................................ 
7) Over the last 3 – 6 months have you taken your
child to the general practitioner?
If yes, how many times and what for ............................
The accompanying women's questionnaire asked women
about their own health, again with additional questions
used only in the UK:
Fertility
1) Have you used contraception since your child was
born?
If yes which ones ............................................................ 
2) Did having pre-eclampsia (toxaemia) contribute to
your choice?
If yes, please explain how ...............................................
3) Have you tried to get pregnant again since your
child was born?
If no, did having pre-eclampsia contribute to your
decision?
Please explain ................................................................ 
Use of health care resources
4) Have you seen anyone else about your health, or
how you feel, since your child was born?
If yes, who and what for? .......................................
Options for response to questions 'Yes' or 'No'
Women were also asked about their experience of partici-
pating in the Magpie Trial. Responses to these questions
are part of a qualitative analysis of participants' views of
being in the trial, and are reported elsewhere [14].
Further assessment of children and women
Children were considered 'screen positive' if they failed
the ASQ, if the ASQ could not be scored, or if the child
passed an ASQ for a younger age group. The families of
these children were contacted by telephone and offered a
home visit for further assessment. Children were consid-
ered screen negative if they passed the ASQ for their own
age group, or for an older child. Screen negative children
in the north east of England were offered a home visit.
The aim of the home visit was to confirm whether or not
the child had neurodevelopmental delay, or any other sig-
nificant problem. If so, to collect information that would,
if possible, establish a diagnosis. Families were asked
about the child's current health and development, and the
child was tested using the Bayley Scales of Infant Develop-
ment (BSID-II) [15]. These assessments were conducted
by a midwife and a psychologist, both trained in use of the
BSID-II, who met every three months and conducted
some joint visits.
During the home visit we took the opportunity to measure
the woman's blood pressure, and to ask her about her health.
Home visits lasted approximately two to three hours. All
assessments were blind to the allocated treatment.
Statistical analyses
Responses by the general practitioner and the family were
described and compared for both women and children. As
information was collected from general practitioners ear-
lier than from families, the aim was to assess whether
these responses were comparable and whether differences
could reasonably be expected to be due to the time differ-
ence. Data assessing the child's behaviour, the woman's
fertility, and their use of health service resources were
compared between the two allocated treatment groups.
Results
Of the 774 UK women included in follow up, 12 were lost
to follow up and three died after discharge from hospital
(Figure 1); data are available for 759 of the 771 surviving
women (98%). Cause of death for the women who died
was stroke (1); asthma (1); and non-Hodgkins lymphoma
(1). Of the 827 children included in follow up, 12 were
lost to follow up, 5 were excluded due to a problem aris-
ing at conception or embryogenesis and 19 died (Figure
2); data are available for 791 of the 803 surviving and nor-
mally formed children (98%). Of the 17 children who
died before discharge from hospital, 13 were randomised
before delivery and 4 after delivery. Four of these babies
were stillborn and 13 died of prematurity. Cause of death
for the two children who died after discharge from hospi-
tal was also prematurity.Page 5 of 11
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659 families returned the children's questionnaire.
Response was after a reminder for 359 families, and the
questionnaire was completed by phone for an additional
47 families. Questionnaires were completed 24 months
(median, inter quartile range 23–31 months) after the child
was born (adjusted for gestation at birth up to 24 months).
There was no difference in the response rate between the
two allocated groups. In addition, there were no clear dif-
ferences between women who responded to the question-
naire (n = 619) and those who did not (n = 140) in
characteristics at trial entry, outcome at delivery or outcome
at discharge following delivery (data not shown).
Of women included in the UK follow up, three quarters
(74%) were primiparous, a quarter were less than 34
weeks gestation at trial entry, just over half (56%) had
labour induced, two thirds (61%) were delivered by cae-
sarean section and nearly half (46%) had severe pre-
eclampsia (data not shown). For 132 children the family
did not complete the questionnaire; but for two the fami-
lies contacted us to say the child had severe disability and
request that they have no further assessment. The remain-
ing 130 children were no more likely to have develop-
mental delay, reported by the general practitioner, than
those children for whom the family completed a ques-
tionnaire (data not shown).
Overall for 688/759 (91%) women the general practi-
tioner's questionnaire was completed. The majority
(62%) responded after the initial questionnaire, some
practices requiring reminders (34%). Fifty-one practices
requested, and were sent, a copy of the trial consent form;
of these 36 responded by returning the completed ques-
Table 1: Comparison of responses for the 551 women for whom there were questionnaires from both general practitioner and 
women
General practitioner Women
n = 551 (%) n = 551 (%)
Visit/s to general practitioner 531 (96) 411 (75)
Number of visits: 191 216
1–5 161 75
6–10 161 75
> 10 168 77
not known 11 43
Visits to hospital clinic 222 (40) 199 (36)
Not known 6 (1) 6 (1)
Admission to hospital 45 (8) 89 (16)
Number of admissions to hospital/year*
Reported at ≤ 24 months **
Median {IQR} 0.63 {0.6–0.7} 0.5 {0.5–1.0}
Range 0–2 0–4
Reported at > 24 months ***
Median {IQR} 0.4 {0.4–0.5} 0.4 {0.3–0.5}
Range 0–1 0–2
not known number of times admitted 7 10
Since Magpie pregnancy
Serious morbidity**** 14 (3) 18 (3)
had antihypertensive since 6 weeks postpartum 126 (23) 107 (19)
not known 7 6
Taking antihypertensive drug now 54 (10) 59 (11)
not known 6 - 2 -
Other prescribed drug/s for > 2 weeks 316 (57) 150 (27)
not known 6 6 -
* excludes admissions related to pregnancy
** general practitioner n = 335, women n = 166
*** general practitioner n = 216, women n = 385,
**** one or more of renal problems, stroke, severe hypertensionPage 6 of 11
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practices (eight also requested a copy of the trial consent
form). Five practices gave no response. No general practi-
tioner could be identified for three women. The general
practitioner's questionnaires were completed 23 months
(median, inter quartile range 19–27 months) after the
child was born (adjusted for gestation at birth up to 24
months). Based on information provided by the general
practitioner we did not contact four families: the reasons
were recent marital breakdown (2), recent death of hus-
band (1) and drug addiction (1).
Comparison of responses from general practitioners and 
families
Questionnaire responses were available from both general
practitioners and women for 551/759 women (Table 1)
and for 580/791 children (Table 2). For the women,
responses were largely comparable although women
reported fewer visits to the general practitioner, and being
prescribed fewer drugs other than antihypertensives, than
did general practitioners. This was despite the general
practitioners completing the questionnaire slightly earlier
than the women. For the children's questionnaires, again
general practitioners reported more visits than did fami-
lies; these data are not directly comparable, however, as
families were only asked to report visits in the last six
months
Outcome for surviving women and children
Women
Overall serious morbidity potentially related to pre-
eclampsia was reported for 31 (4%) women recruited in
the UK; of whom 26 had severe hypertension (defined as
taking two or more antihypertensives at time of complet-
ing questionnaire), six had renal problems, and one
woman had had a stroke. Other morbidity was reported
for 331 (44%) women, this included: minor ailments
(colds, flu, diarrhoea and vomiting, backache) for 235
(31%) women, major psychiatric illness (psychosis or
depression requiring treatment) for 144 (19%) and minor
psychiatric illness (stress or anxiety not requiring treat-
ment) for 49 (6%). Women's reporting of their fertility
since the Magpie Trial and family history of pre-eclampsia
and use of health care resources are in Table 3.
Children
Over 30% of children were reported to have been admit-
ted to hospital: chest infection and minor surgery being
the most common reasons. Other morbidity was reported
for 149 (26%) children, this included: minor ailments
(allergic reactions, coughs, colds, ear infections). Pre-
scribed medication for more than two weeks was reported
for 126 (25%) children: these included vitamins (29%),
asthma treatment (25%) and antibiotics (19%) (Table 2).
There were no clear differences between the randomised
Table 2: Comparison of responses for 580 children for whom there were questionnaires from both general practitioner and family
General practitioner Family
n = 580 (%) n = 580 (%)
Visit/s to general practitioner
Since birth 569 (98)
In 6 months preceding questionnaire 295 (51)
Medication prescribed by general practitioner* 196 (34) 154 (27)
Admission to hospital 168 (30) 221 (38)
Reasons:
Respiratory infection 54 56
Minor surgery 35 38
Gastro-enteritis 33 24
Other 46 103
Number of admissions to hospital/year
Assessed at ≤ 24 months**
Median {IQR} 0.7 {0.6–1.2} 0.5 {0.5–1.0}
Range 1–3 1–3
Assessed at > 24 months***
Median {IQR} 0.4 {0.4–0.8} 0.4 {0.3–0.6}
Range 1–4 1–4
not known number of times admitted 28 2
*medications (vitamin/mineral supplement, skin treatment, asthma treatment, gastro-intestinal/laxative, antibiotics)
** general practitioner n = 328, children n = 253
*** general practitioner n = 252, children n = 327Page 7 of 11
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The sole exception was children randomised magnesium
sulphate were more likely to play happily with other chil-
dren than those randomised placebo (RR 1.10 CI 1.02
to1.18). Of the 671 children with a completed question-
naire, the ASQ could be scored for 659 (98%).
Discussion
Data presented here provide further reassurance about the
longer term safety of magnesium sulphate when used for
women with pre-eclampsia. There appears to be no sub-
stantive effect on women's' subsequent fertility, or their
use of health care services in the two years after the birth.
As magnesium sulphate is associated with cerebral
vasodilatation, and is a blocker of N-methyl-D-aspartate
(NMDA) receptors in the brain, the pathway for anoxic
cell damage, we hypothesized that in utero exposure might
influence a child's development and behaviour. Data
from the main Magpie Trial follow up study have already
demonstrated that magnesium sulphate has no clear effect
on the child's risk of severe neurodevelopmental delay
[9]. These additional data from the UK provide further
reassurance that in utero exposure to magnesium sulphate
does not appear to have a major influence on behaviour
Table 3: Fertility, history of pre-eclampsia, and use of health care resources reported by the women
MgSO4 Placebo
n = 303 (%) n = 316 (%)
Contraception
Used since Magpie Trial 219 (72) 245 (78)
Not known - - 1 -
Decision about contraception influenced by pre-eclampsia 52 (17) 56 (18)
Not known 19 (6) 21 (7)
Reason given*:worried about having pre-eclampsia again 15 29
advised not to take pill 22 14
advised not to have/did not want more children 9 3
not known 9 11
Fertility
Has not tried to get pregnant again 215 (71) 219 (69)
Not known 1 2
Decision not to get pregnant influenced by pre-eclampsia 91 (30) 94 (30)
Not known 37 (12) 40 (13)
Reason given*:pre-eclampsia unpleasant experience 55 64
did not enjoy pregnancy 11 8
pre-eclampsia in previous pregnancy 8 7
advised not to get pregnant 5 6
would like to know more 3 3
other 13 12
not known 9 6
Pregnancy since Magpie Trial 83 (27) 84 (27)
Pregnant now 24 23
Has had pre-eclampsia again 13 (4) 14 (4)
Not known 25 26
Family history of pre-eclampsia** 79 (26) 87 (28)
1st degree relative 80 81
2nd degree relative 16 21
not known 5 10
Help from other health care worker 34 11 46 15
Health care worker 15 22
Psychiatric services 14 11
Alternative therapist 5 10
Not known - 3
* some women gave more than 1 reason
** some women had more than one relativePage 8 of 11
(page number not for citation purposes)
BMC Pregnancy and Childbirth 2009, 9:15 http://www.biomedcentral.com/1471-2393/9/15at two years of age. The sole exception was that children of
women randomised to magnesium sulphate were more
likely to be reported as playing happily with others, than
those of women randomised to placebo. Although this
result is reassuring, it may reflect the play of chance and
therefore should be interpreted with caution.
The high response rate to the postal questionnaires is a
key strength of our study. By sending questionnaires to
both the families and general practitioners we were able to
achieve 98% follow up. For families we were unable to
contact, or who did not respond to the questionnaire,
information was provided by their general practitioner.
Comparison of these responses is reassuring, in that they
are largely comparable. This is consistent with the agree-
ment between a parental questionnaire and paediatric
assessment for children with a high prevalence of impair-
ment [16]. The main differences between the two sources
of information were that women and families reported
fewer visits to the general practitioner, and women
reported more visits to hospital and fewer prescribed
drugs that were not antihypertensives. As visits to the gen-
eral practitioner were so frequent, it is not surprising that
families tended to underestimate the number. The higher
reporting of hospital admission by women may reflect
women counting attendance at a day unit as hospital
admission, with general practitioners only counting over-
night stays.
The follow up study did not begin until after recruitment
closed, as this was when funding was secured. Neverthe-
less, use of the Office for National Statistics ensuring com-
plete ascertainment of mortality, and accessing the
National Health Service Tracing Scheme enabled us to
trace all but four surviving mothers and their four chil-
dren. An additional advantage of the separate system for
Table 4: Reported behaviour for children with a completed questionnaire
Randomised before delivery
MgSO4
n = 308 (%)
Placebo
n = 301 (%)
Total responded to questionnaire 250 81% 254 84%
Does your child play happily alone for up to 10 minutes?
Yes 210 (84) 201 (79)
Sometimes 33 40
No 1 3
not answered 6 10
Is your child frightened in new situations?
Yes 28 (11) 34 (14)
Sometimes 149 135
No 66 70
not answered 7 15
Does your child play happily with other children if you are around?
Yes* 220 (88) 204 (80)
Sometimes 22 34
No 1 5
not answered 7 11
Does your child cling to you when you are with other people?
Yes 29 (12) 35 (14)
Sometimes 127 126
No 87 81
not answered 7 12
Does your child settle easily to sleep through the night?
Yes 157 (63) 164 (65)
Sometimes 49 43
No 36 36
not answered 8 11
No response to questionnaire 58 19% 47 16%
*MgSO4 versus placebo = RR 1.810 [CI 1.0210–1.182.94]Page 9 of 11
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tacting families if the child had died could be avoided,
and if the mother died an appropriate approach could be
made to the child's current carer.
Fewer families responded to the questionnaires than did
the general practitioners. Our children's questionnaire
asked for the child's current height and weight, informa-
tion that was often missing from questionnaires returned.
Some families told us they delayed returning question-
naires in order to take the child to a clinic to be weighed
and measured. It is seems likely that this delay contrib-
uted to the non-response. As the data for height and
weight were incomplete, they have not been reported. Our
impression is that women and families largely valued
being contacted for the follow up study. Only 12 families
chose to opt out. Women returning the questionnaires,
and being contacted for a home visit, often expressed their
appreciation of our continued interest in their, and their
child's, health and welfare. In addition, the questionnaire
to women included three questions about their views of
participation in the Magpie Trial, these data are reported
elsewhere[14].
Data presented here provide further confirmation of the
considerable morbidity experienced by women following
childbirth. There is a growing awareness of the high level of
health problems women experience, even after an uncom-
plicated pregnancy and childbirth [17]. Around 14% of
women report health problems (such as back pain, exhaus-
tion, anaemia, haemorrhoids, headaches and emotional
difficulties) in the first eight weeks after the birth, and 10%
in the subsequent 12–18 months[18] For women with pre-
eclampsia, who are more likely to have had complications
such as caesarean section or preterm birth, long term mor-
bidity is probably higher[18]. In the Magpie Trial follow up
study overall, only one third of women did not report any
health problems, and even this may represent under report-
ing [10]. Women in the UK reported similar levels of health
problems to women in other countries who participated in
the Magpie Trial[10]. However, mental health problems
were reported by a quarter of women in the UK, compared
to just 6% of women overall in the follow up study [10].
This difference probably reflects substantial under ascer-
tainment in low and middle income countries [10]. As our
UK data are based on self reporting and information from
general practitioners, the true level of mental health mor-
bidity may be even higher; some women may not have rec-
ognised their symptoms or discussed them with their
general practitioner. The high level of depression and anxi-
ety after childbirth is important not only in its conse-
quences for the woman, but also because it has been shown
to be associated with impaired child development [19-22]
Further understanding of how to prevent these adverse out-
comes is required.
Conclusion
Magnesium sulphate reduces the risk of eclampsia [8]
without any substantive effect on longer term morbidity
and mortality for the women or children [9,10]. Data pre-
sented here provide further reassurance about the longer
term safety of magnesium sulphate when used for women
with pre-eclampsia: there appears to be no influence on
women's' fertility or her use of health care services, nor on
the child's development or behaviour in early childhood.
Sending postal questionnaires to families and general
practitioners to assess the health of women and children
is feasible, and can achieve a high response.
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